Therapeutic Targeting of Alternative Splicing: A New Frontier in Cancer Treatment

Area of Science:

• Molecular Biology
• Cell Biology
• Cancer Biology

Background:

• Alternative splicing diversifies the proteome, enabling complex cellular functions and adaptation.
• The spliceosome, a complex of proteins and RNA, executes alternative splicing.
• Dysregulation of splicing, including spliceosome and splicing factor abnormalities, contributes to cancer development and progression.

Purpose of the Study:

• To review the process of alternative splicing and its aberrant forms in cancer.
• To highlight the role of serine/arginine-rich (SR) proteins in cancer development and progression.
• To discuss emerging therapeutic strategies targeting the spliceosome and alternative splicing in cancer treatment.

Main Methods:

• Literature review of alternative splicing mechanisms.
• Analysis of the role of splicing factors, particularly SR proteins, in oncogenesis.
• Examination of recent advancements in spliceosome mapping and its therapeutic implications.

Main Results:

• Alternative splicing is crucial for cellular adaptability and proteome diversity.
• Aberrant splicing, often driven by altered splicing factors like SR proteins, is a hallmark of cancer.
• Recent research has elucidated the spliceosome's role in cancer, paving the way for targeted therapies.

Conclusions:

• Understanding alternative splicing and its dysregulation in cancer is critical for developing novel treatments.
• Serine/arginine-rich proteins are key players in spliceosome-mediated oncogenesis.
• Small molecule inhibitors targeting the spliceosome represent a promising frontier in cancer therapy.